An observational study in Acute Respiratory Distress Syndrome and Barotrauma, sponsored by Università Vita-Salute San Raffaele. Recruiting at 4 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Università Vita-Salute San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in Respiratory Distress Syndrome with a site in Italy — 21 open to participants now, 24 under way, 2 of them phase 3. Respiratory Distress Syndrome · Italy.
Among the 91 studies in Respiratory Distress Syndrome with a site in Italy, this one is the 20th largest by planned enrollment of the 39 observational ones that give a count, is one of 8 that started in 2023, is one of 40 observational ones, reaches primary completion later than 16 of the 23 other live ones, and was the 81st registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →21 of the 91 studies in Respiratory Distress Syndrome with a site in Italy are open now. Recruiting first, the newest first:
Istituto Clinico Humanitas · Sites in Italy
Ages 18+
University of Padova · Sites in Italy
Ages 18+ · Healthy volunteers
University College Dublin · Sites in Italy, Croatia, Czechia and 6 more countries
Ages 0 min–28 days
University of Bologna · Sites in Italy
Ages 18–100
BioAegis Therapeutics Inc. · Sites in Italy, United States, Belgium and 10 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 11 · Phase 3 11
First in 2002; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is close to the median of 100 across 476 observational studies indexed under Respiratory Distress Syndrome.
Median enrollment 50 across the 49 interventional studies, 110 across the 39 observational. Of the 49 that completed or were terminated, 6 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 91 have an industry lead sponsor. The 10 most frequent:
Università Vita-Salute San Raffaele is the lead sponsor of 86 studies on the registry; 33 are open to participants now.
Università Vita-Salute San Raffaele has 3 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
11 of the studies in Respiratory Distress Syndrome with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT04460859Unity Health TorontoRecruitmEnt Assessed by eleCtRical Impedance Tomography | 2026-12 |
| NCT07402174Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoEIT- Guided Lung Recruitment in pARDS | 2026-12-01 |
| NCT07686315Istituto Clinico HumanitasAdvanced Respiratory Monitoring for Safer Mechanical Ventilation in Patients Without Respiratory Failure | 2026-12-30 |
| NCT04903262University of BolognaUltra-Protective Lung Ventilation With Extracorporeal CO2 Removal for Moderate ARDS | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 91 studies in Respiratory Distress Syndrome with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Barotrauma (pneumothorax, pneumomediastinum) is a well-described complication of Acute Respiratory Distress Syndrome (ARDS), especially in patients with coronavirus disease 2019 (COVID-19) (16.1% in COVID-19, and about 6% in non-COVID-19 ARDS). Macklin effect was recently discovered by our group as an accurate radiological predictor of barotrauma in COVID-19 ARDS; the Investigators also found that density histograms automatically extracted from chest CT images provide a reliable insight into lung composition
. Since lung frailty is a major issue also in non-COVID-19 ARDS, the Investigators want to confirm the predictive role of Macklin effect also in this setting. In addition, the Investigators aim to explore inflammatory profiling to decipher different biological aspects of the same clinical issue. Finally, the Investigators want to develop a specific management algorithm for patients diagnosed, according to our findings, with a specific ARDS sub phenotype characterized by increased lung frailty
Barotrauma occurs frequently in acute respiratory distress syndrome (ARDS), and has a difficult, non-standardized management. Unfortunately, mortality rates remain high (> 60% in COVID-19 ARDS, around 46% in non-COVID-19 ARDS). Interestingly, data from COVID-19 patients suggested that barotrauma may occur also in spontaneously breathing patients with ARDS. Accordingly, frailty of lung parenchyma represents a major issue in ARDS. Protective mechanical ventilation (i.e. ventilation with low tidal volume and low airway pressures) remains a cornerstone of supportive management of ARDS. Unfortunately, mechanical ventilation may worsen pulmonary damage (ventilator-induced lung injury) and, in high-risk patients, may induce barotrauma even when ventilator settings are maintained within the "safe" limit of protective ARDS. Early identification of high-risk features could therefore allow clinicians to individualize management of high-risk patients, by tailoring respiratory support and potentially select candidates for advanced support (i.e. extracorporeal membrane oxygenation) before development of overt barotrauma.
Macklin effect is a well-described radiological sign originally intended to differentiate between "peripheral" (distal airway rupture, "respiratory" barotrauma) and "central" (lesion to large airways/esophaegal injury) causes of air leakage in the mediastinum. However, the Investigators recently identified Macklin effect as a strong radiological predictor of barotrauma development in mechanically ventilated COVID-19 ARDS patients (sensitivity: 89.2%; specificity: 95.6%). In our cohort, radiologically-detected Macklin effect was identified 8-12 days before development of pneumomediastinum/pneumothorax. These preliminary results have been confirmed in a subsequent multicenter study (sample size 697 patients; sensitivity: 100%; specificity: 99.8%).
Furthermore, preliminary data suggest that early application of awake veno/venous extracorporeal membrane oxygenation (ECMO) before invasive mechanical ventilation in COVID-19 patients with severe ARDS and at high-risk for barotrauma (defined as presence of Macklin effect on chest CT imaging) might result in no barotrauma events with a low intubation rate.
Concurrently, a hyper inflammatory sub phenotype has been associated with overall worse outcome both in terms of mortality and ventilator-free days in ARDS. Moreover, the occurrence of lung injury during mechanical ventilation has been proven to be significantly related to the recruitment of mast cells via CXCL10/CXCR3 signaling .
In this view, confirmation of Macklin effect predictive role and identification of further, novel laboratory biomarkers could provide instruments for early risk stratification in ARDS patients.
Taken together, i) quantitative imaging analysis and ii) systemic inflammatory profiling could decipher different biological aspects of the same clinical issue, possibly laying foundation for the definition of a multimodality signature of lung frailty in ARDS patients..
Accordingly, the driving hypotheses of this retrospective/prospective study is that identification of a novel ARDS sub phenotype characterized, irrespective of the underlying etiology, by increased lung frailty could substantially improve the poor prognosis routinely associated with this condition, possibly being a landmark for personalized management strategies.
To further validate the role of Macklin effect, the Investigators will:
In the main prospective study, the Investigators will:
Patients with ARDS diagnosis will be enrolled. With the exception of blood and BAL samples collection, all patients enrolled in the prospective cohort will follow their normal course of diagnosis/treatment without any further requirements for the scope of this study other than those provided in the normal management of patients with this condition. Furthermore, any decision regarding drug or procedure will be made by the physician based on her/his clinical judgment, independently from the decision to include the patient in this study. No follow-up medical and/or imaging examinations/laboratory analysis after hospital discharge are needed by the present study design.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with ARDS requiring or not requiring invasive ventilation
Diagnostic Test: Blood and bronchoalveolar fluid collection and analysis · Diagnostic Test: Chest CT scan
Blood and bronchoalveolar lavage fluid will be collected within 12 hours after intubation. Blood samples will be centrifuged, and the serum immediately stored at less than 70° C. The following biomarkers will be analysed in the serum and bronchoalveolar lavage fluid: Interleukin-8 (IL-8), Interleukin (IL)-6, IL-1Ra, IL-18, interferon (IFN ), Angiopoietin-2 (Ang-2), Tumour Necrosis Factor receptor-1 (TNFr1), Plasminogen Activator Inhibitor-1(PAI-1), Receptor for Advanced Glycation Endproducts (RAGE), Intercellular adhesion molecule-1 (ICAM-1), Surfactant Protein D (SPD), protein C, Von Willebrand Factor (VWF), CXCL10/CXCR3, and metalloproteases (MMP9, MMP10). Blood samples obtained from the patients will be placed in specimen tubes containing heparin, centrifuged at 1500 G for 10 minutes, and then the plasma will be aspirated and stored at -70° C. Bronchoalveolar lavage fluid will be centrifuged at 1500 G for 10 minutes to remove cellular contents and stored at -70° C.
Computed Tomography Scan per normal clinical practice
Rate of clinically relevant barotrauma
Barotrauma is diagnosed only in the case of clear radiological evidence (free air at chest X-ray and/or chest CT scan). Rate of barotrauma will be compared between patients with an hyperinflammatory pattern as compared with control.
Time frame: 30 days or until hospital discharge. Specifically, from date of basal CT scan until the date of first radiologically documented barotrauma
Plan to share: No
Started Nov 2023 (actual). Primary completion is estimated for Apr 2027, 41 months after the start.
Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 41 months is above that.
Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
Università Vita-Salute San Raffaele